ANVS approves transfer of licences of NRG and PALLAS
NRG and PALLAS plan to merge to create a single organisation. The ANVS has approved the transfer of their licences into the new organisation. The new organisation will continue the existing operations of both companies. NRG’s activities include making medical isotopes that are used in cancer treatment. You can submit an objection to our decision until 25 September 2024.
Aerial view of the Petten site, including NRG's High Flux Reactor and the PALLAS reactor construction site.
Existing licences
NRG has a licence to operate the High Flux Reactor (HFR) in Petten. This is a research reactor that currently produces medical isotopes. NRG also has a licence to operate other facilities, including a radioactive waste storage facility. PALLAS has a licence for the construction of a new research reactor in Petten, which will replace the HFR. Construction of the new PALLAS reactor (in Dutch) has already begun.
Nuclear safety is protected
In our assessment, we analysed the new organisation’s nuclear safety measures. We focused on three areas in particular. Firstly, whether sufficient expertise is in place. Secondly, whether the organisation is reliable. Thirdly, whether sufficient funding is available to operate nuclear facilities safely. We conclude that this is indeed the case for all three focus areas. Therefore, in our decision (in Dutch) we have authorised the transfer of the licences.
Objections may be submitted until 25 September 2024
Stakeholders can submit objections to our decision up to and including 25 September 2024. The notice of objection must include the signature, date, name and address of the objector. It must also clearly state the reason for objecting to this decision.
Send your notice of objection to:
Authority for Nuclear Safety and Radiation Protection
P.O. Box 16001
2500 BA The Hague
Please state ‘letter of objection’ on the envelope.